Related Experiment Videos
[The predictive parameters in the response to almitrine treatment]
J M González Ruiz1, J Villamor, J M Pino
1Servicio de Neumología, Hospital Clínico de Salamanca, Madrid.
Archivos De Bronconeumologia
|March 1, 1994
Summary
Almitrine bimesylate (AB) can improve hypoxemia in some patients with chronic obstructive bronchitis. Patients with lower baseline CO2 occlusion pressure and inspiratory flow may benefit most from this treatment.
Area of Science:
- Pulmonary Medicine
- Respiratory Physiology
Background:
- Almitrine bimesylate (AB) is a known treatment for hypoxemia.
- Its efficacy varies, and patient selection is crucial for optimal outcomes.
Purpose of the Study:
- To identify predictors of response to almitrine bimesylate (AB) in patients with chronic obstructive bronchitis.
- To determine which patients are most likely to benefit from AB treatment.
Main Methods:
- A 3-month, double-blind, placebo-controlled study involving 21 patients with chronic obstructive bronchitis on home oxygen therapy.
- Patients received either AB (50-100 mg/day) or a placebo.
- Gasometric variables and respiratory function were assessed.
Main Results:
- Almitrine bimesylate (AB) significantly increased PaO2 in treated patients (p < 0.05).
- Responders (PaO2 increase > 5 mmHg) had lower baseline CO2 occlusion pressure, mean inspiratory flow, and minute ventilation compared to non-responders.
- These baseline variables were identified as potential predictors of AB response.
Conclusions:
- CO2 occlusion pressure, mean inspiratory flow, and minute ventilation can predict gasometric response to almitrine bimesylate (AB).
- These findings aid in selecting patients likely to benefit from AB for hypoxemia associated with chronic obstructive bronchitis.